Clearside BiomedicalCLSDQ 49 OCF Yield % is -3,255.81 as of Jul. 06, 2026. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Clearside Biomedical ranks worse than 99.72% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Clearside Biomedical OCF Yield % Related Terms
Clearside Biomedical OCF Yield % Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Clearside Biomedical's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (CLSDQ) has a OCF Yield % of -3,255.81 as of Jul. 06, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #1406 out of 1410 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Clearside Biomedical's OCF Yield % too high?
Clearside Biomedical's current OCF Yield % is -3,255.81. Based on the distribution chart, Clearside Biomedical ranks #1406 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's OCF Yield % compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #1406 out of 1410 companies for OCF Yield %. This places Clearside Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current OCF Yield % is -3,255.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current OCF Yield % is -3,255.81. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current OCF Yield % is -3,255.81 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (CLSDQ) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34.
GuruFocus considers Clearside Biomedical to be Possible Value Trap.
Key valuation signals for CLSDQ:
OCF Yield %: -3,255.81
GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for CLSDQ
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLSDQ has been successfully added to your 
